XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Income Statement [Abstract]        
Molecular diagnostic testing $ 179.2 $ 183.9 $ 358.0 $ 348.9
Pharmaceutical and clinical services 14.8 12.6 26.2 25.0
Total revenue 194.0 196.5 384.2 373.9
Costs and expenses:        
Cost of molecular diagnostic testing 37.7 37.4 73.9 71.6
Cost of pharmaceutical and clinical services 6.7 7.0 13.5 12.7
Research and development expense 16.8 18.6 34.6 38.0
Change in the fair value of contingent consideration 13.0 (3.8) (60.2) (3.2)
Selling, general, and administrative expense 115.4 120.3 230.5 232.2
Total costs and expenses 189.6 179.5 292.3 351.3
Operating income 4.4 17.0 91.9 22.6
Other income (expense):        
Interest income 0.4 0.3 0.8 0.6
Interest expense (0.7) (2.6) (1.7) (3.3)
Other (0.4) (2.6) (0.7) (3.8)
Total other income (expense): (0.7) (4.9) (1.6) (6.5)
Income before income tax 3.7 12.1 90.3 16.1
Income tax provision (28.4) 6.2 (22.8) 11.4
Net income 32.1 5.9 113.1 4.7
Net loss attributable to non-controlling interest     (0.1)  
Net income attributable to Myriad Genetics, Inc. stockholders $ 32.1 $ 5.9 $ 113.2 $ 4.7
Earnings per share:        
Basic $ 0.46 $ 0.09 $ 1.64 $ 0.07
Diluted $ 0.45 $ 0.09 $ 1.59 $ 0.07
Weighted average shares outstanding:        
Basic 69.3 68.2 68.9 68.5
Diluted 71.9 68.3 71.2 68.9